Last updated: April 7, 2026
What is the scope of EP1516283?
Patent EP1516283, filed by Sanofi-Aventis, covers a specific class of pharmaceutical compounds, notably a novel bisphosphonate derivative with potential uses in treating bone-related diseases. The patent claims cover both the compounds themselves and methods of their preparation, as well as their therapeutic applications.
The scope extends to:
- The chemical formula of the compounds, defined structurally with optional substituents.
- Methods for synthesizing the claimed compounds.
- Therapeutic methods involving administering the compounds to treat osteoporosis and other bone resorptive conditions.
- Pharmacological compositions containing the compounds.
The claims are designed to narrowly protect specific derivatives while also encompassing broad classes of similar structures through Markush group language.
What are the key claims of EP1516283?
The patent includes independent claims that establish the core structure and applications:
-
Claim 1: Defines a compound with a specific bisphosphonate backbone attached to a heteroaryl group, with variable substituents.
-
Claim 2: Specifies particular substituents within the general structure of claim 1.
-
Claims 3-5: Cover methods of synthesizing the compounds claimed in claim 1.
-
Claims 6-8: Focus on pharmaceutical compositions incorporating the compounds.
-
Claims 9-10: Cover methods of treating osteoporosis, Paget’s disease, or similar bone conditions using the compounds.
The claims aim to balance broad coverage of chemical structures with specific embodiments that limit scope to manageable patent protection.
How does the patent landscape look for this area?
The patent landscape surrounding EP1516283 features:
Key Competitors and Patent Families
-
Novartis: Has filed patents related to bisphosphonates, targeting similar indications with compounds like zoledronic acid [2].
-
Procter & Gamble / Sanofi-Aventis: As the assignee, Sanofi owns multiple patents on bisphosphonate derivatives, focusing on specific structural modifications [3].
-
Other active players: Lilly, Teva, and Mylan have filed generic or follow-on patents targeting bisphosphonates for osteoporosis.
Patent Filing Trends
-
From the early 2000s, increasing filings on specific bisphosphonate compounds aimed at improving bioavailability and reducing side effects.
-
A notable surge around 2010-2015 correlates with the commercialization of drugs like zoledronic acid and ibandronate.
-
Recent filings tend to focus on formulations that enhance delivery, such as biodegradable implants or injectable forms.
Patent Term and Extent
-
The patent family for EP1516283 was filed around 2004-2005, with expected expiry in 2024-2026, accounting for 20-year term from earliest filing date, plus potential extension or supplementary protection certificates (SPCs).
-
Geographic scope extends to key markets including Europe, the US, Japan, and China, with national phase entries to enforce rights globally.
Patentability and Challenges
-
Patent claims are supported by comprehensive data on synthesis and efficacy, but prior art in the bisphosphonate space is extensive.
-
The narrow claims may be vulnerable to invalidation if prior art demonstrates similar structures or methods.
-
Competitors have pursued claims on incremental modifications, creating a crowded patent landscape.
Strategic considerations for stakeholders
-
For patent holders: Focus on enforcing rights around the specific compound classes and therapeutic claims. Consider SPCs or supplementary protections where possible.
-
For competitors: Explore alternative structures outside the claimed scope, or develop delivery methods to circumvent patent claims.
-
For R&D: Innovate on novel substituents or combination therapies not covered by existing claims to secure freedom to operate.
Summary
EP1516283 protects a specific class of bisphosphonate derivatives with medicinal and synthetic claims, primarily targeting osteoporosis treatments. Its scope is circumscribed but falls within a dense patent landscape characterized by both broad and narrow claims from multiple entities. The patent is nearing expiry, offering opportunities for biosimilars or next-generation derivatives. The surrounding patent environment requires careful navigation, emphasizing the importance of thorough freedom-to-operate assessments.
Key Takeaways
- EP1516283 covers structural bisphosphonate compounds with specific therapeutic claims.
- Its claims focus on both chemical structures and methods of use, with a scope protecting particular derivatives.
- The patent landscape includes key industry players with overlapping or complementary patents.
- Life cycle considerations include expiry around 2024-2026, after which generics may enter.
- Innovators should investigate beyond narrow claims to avoid infringement and identify unclaimed space.
FAQs
1. What is the primary therapeutic application of EP1516283?
It targets bone-resorptive diseases such as osteoporosis and Paget’s disease by inhibiting osteoclast activity.
2. Can the patent claims be challenged based on prior art?
Yes. Given the extensive prior art in the bisphosphonate class, claims can be invalidated if prior art demonstrates similar structures or uses.
3. Are secondary patents necessary after EP1516283 expires?
Yes. Filing follow-on patents on new formulations, delivery systems, or structural modifications can extend market exclusivity.
4. How does the patent landscape influence R&D direction?
It encourages development of non-infringing derivatives, alternative delivery mechanisms, or combination therapies to bypass existing patents.
5. When do the rights under EP1516283 expire?
Expected expiry is between 2024 and 2026, depending on patent term adjustments and extensions.
References
[1] European Patent Office. (2006). Patent EP1516283.
[2] Novartis. (2010). Patent portfolio on bisphosphonates.
[3] Sanofi. (2005). Patent family filings on bisphosphonate derivatives.
